PMID- 32561286
OWN - NLM
STAT- MEDLINE
DCOM- 20210126
LR  - 20211121
IS  - 1090-2422 (Electronic)
IS  - 0014-4827 (Linking)
VI  - 394
IP  - 1
DP  - 2020 Sep 1
TI  - Insulin exacerbated high glucose-induced epithelial-mesenchymal transition in 
      prostatic epithelial cells BPH-1 and prostate cancer cells PC-3 via MEK/ERK 
      signaling pathway.
PG  - 112145
LID - S0014-4827(20)30392-X [pii]
LID - 10.1016/j.yexcr.2020.112145 [doi]
AB  - As two most common progressive diseases of aging, type 2 diabetes mellitus (T2DM) 
      and benign prostatic hyperplasia (BPH) were all characterized by endocrine and 
      metabolic disorders. Here, our clinical study showed that there were significant 
      differences in fasting blood glucose (FBG), fasting insulin (FINS), insulin 
      resistance index (HOMA-IR) and prostate volume (PV) between simple BPH patients 
      and BPH complicated with T2DM patients. Further analysis showed that HOMA-IR was 
      positively correlated with PV in BPH complicated with T2DM patients. The in vitro 
      experiment results showed that high glucose (HG) promoted EMT process in a 
      glucose-dependent manner in human prostate hyperplasia cells (BPH-1) and prostate 
      cancer cells (PC-3), and this pathological process was exacerbated by co-culture 
      with insulin. Mechanistically, insulin-induced exacerbation of EMT was depended 
      on the activation of MEK/ERK signaling pathway, and we suggested that insulin and 
      its analogs should be used very carefully for the clinical antihyperglycemic 
      treatment of BPH complicated with T2DM patients.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Yang, Tingting
AU  - Yang T
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, 221004, China.
FAU - Zhou, Yi
AU  - Zhou Y
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, 221004, China.
FAU - Wang, Haiyan
AU  - Wang H
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, 221004, China.
FAU - Chen, Shangxiu
AU  - Chen S
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, 221004, China.
FAU - Shen, Mengli
AU  - Shen M
AD  - Department of Pharmacy, The 7th People's Hospital of Zhengzhou, Zhengzhou, 
      450016, China.
FAU - Hu, Yinlu
AU  - Hu Y
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, 221004, China.
FAU - Wang, Tao
AU  - Wang T
AD  - Department of Pharmacy, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, 221006, China.
FAU - Liu, Junjie
AU  - Liu J
AD  - Department of Urology, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou, 221006, China.
FAU - Jiang, Zhenzhou
AU  - Jiang Z
AD  - Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, 
      Nanjing, 210009, China.
FAU - Wang, ZhongJian
AU  - Wang Z
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, 221004, China.
FAU - Zhu, Xia
AU  - Zhu X
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, 221004, China.
FAU - Qian, Sitong
AU  - Qian S
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, 221004, China.
FAU - Yin, Xiaoxing
AU  - Yin X
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, 221004, China.
FAU - Lu, Qian
AU  - Lu Q
AD  - Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical 
      University, Xuzhou, 221004, China. Electronic address: prainry@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200616
PL  - United States
TA  - Exp Cell Res
JT  - Experimental cell research
JID - 0373226
RN  - 0 (Insulin)
RN  - EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
EIN - Exp Cell Res. 2021 Dec 15;409(2):112923. PMID: 34801562
MH  - Epithelial Cells/drug effects/metabolism
MH  - Epithelial-Mesenchymal Transition/drug effects/physiology
MH  - Glucose/*metabolism/*pharmacology
MH  - Humans
MH  - Insulin/*pharmacology
MH  - Insulin Resistance/physiology
MH  - Male
MH  - Mitogen-Activated Protein Kinase Kinases
MH  - Prostate/drug effects/metabolism
MH  - Prostatic Hyperplasia/*drug therapy/metabolism/pathology
MH  - Prostatic Neoplasms/drug therapy/metabolism/*pathology
MH  - Signal Transduction/drug effects
OTO - NOTNLM
OT  - Benign prostatic hyperplasia
OT  - Epithelial-mesenchymal transition
OT  - High glucose
OT  - Insulin
OT  - MEK/ERK signaling Pathway
OT  - Type 2 diabetes mellitus
EDAT- 2020/06/21 06:00
MHDA- 2021/01/27 06:00
CRDT- 2020/06/21 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/05/13 00:00 [revised]
PHST- 2020/06/08 00:00 [accepted]
PHST- 2020/06/21 06:00 [pubmed]
PHST- 2021/01/27 06:00 [medline]
PHST- 2020/06/21 06:00 [entrez]
AID - S0014-4827(20)30392-X [pii]
AID - 10.1016/j.yexcr.2020.112145 [doi]
PST - ppublish
SO  - Exp Cell Res. 2020 Sep 1;394(1):112145. doi: 10.1016/j.yexcr.2020.112145. Epub 
      2020 Jun 16.